Hematology / Oncology CE Activities

Harnessing the Full Potential of Frontline Immunotherapy in Advanced NSCLC: Proceedings from a Clinical Olympics℠

1.0 CE Credit(s)

Current and Emerging Therapies for Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

CE Credit Expired

Seeing Nonmelanoma Skin Cancers Through a New Lens: The Role and Place of Immunotherapy

1.0 CE Credit(s)

Nonmelanoma Skin Cancers, Immunotherapies, and Role of Dermatology Clinicians: A Care Team Forum^®

0.75 CE Credit(s)

Hematology / oncology blog

Targeting BCMA: A New Path in Relapsed/Refractory Multiple Myeloma

In triple- and quad-refractory myeloma, median survival was only about 9 months, and less than 6 months in penta-refractory disease.

Hematology / Oncology
Blog

Navigating Immunotherapy in Advanced NSCLC: What Every Oncologist Should Know

The advent of immunotherapy has significantly extended survival and revolutionized care in advanced non-small cell lung cancer (NSCLC).

Hematology / Oncology
Blog

Is Immunotherapy Right for Your Patient with Nonmelanoma Skin Cancer?

The primary goal of treatment in nonmelanoma skin cancer (NMSC) is tumor elimination with maximal preservation of function and cosmesis.

Hematology / Oncology
Blog

RMEI Presentations

Answering the Call to Action: How Nurses Have Become Progressively More Involved in Immunotherapy IME (2018 to Present)

Optimizing treatment in BCC and CSCC: 3 years of oncology CME

Iterative Data-Driven Education for Evolving Strategies of Care in cSCC

When the Patient Voice is Heard in Education, Does the Clinician Listen?

RMEI DECISION SUPPORT AIDS

Intravitreal Anti-VEGF & Bispecific Therapies for DME & nAMD

In late 2022, the ocular implant, insertion tool assembly, (including the drug vial & initial fill needle) for ranibizumab PDS were voluntarily recalled due to septum dislodgement and paused implantations including ongoing global clinical trials; this did not include the refill vial and needle.

Hematology / Oncology
Decision Support Aid

Cervical Cancer: What You Need to Know About Screening, Symptoms, and Treatments

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients. An estimated 13,960 women are diagnosed with invasive cervical cancer every year.

Hematology / Oncology
Decision Support Aid

Seeing Nonmelanoma Skin Cancers Through A New Lens: The Role and Place of Immunotherapy

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

Hematology / Oncology
Decision Support Aid

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

Hematology / Oncology
Decision Support Aid

LATEST HEMATOLOGY / ONCOLOGY ARTICLES

Latest Hematology / Oncology Articles

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer May 31, 2025
In patients with PIK3CA-mutated advanced breast cancer, inavolisib added to palbociclib–fulvestrant led to a significant overall survival benefit, with a higher incidence of certain toxic effects than placebo.
Komal L. Jhaveri, Seock-Ah Im, Cristina Saura, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Eirini Thanopoulou, Noopur Shankar, Yanling Jin, Thomas J. Stout, Tiffany D. Clark, Chunyan Song, Dejan Juric, Nicholas C. Turner
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer May 31, 2025
In advanced breast cancer, progression-free survival was significantly longer with vepdegestrant than with fulvestrant among patients with ESR1 mutations but not in the full patient population.
Mario Campone, Michelino De Laurentiis, Komal Jhaveri, Xichun Hu, Sylvain Ladoire, Anne Patsouris, Claudio Zamagni, Jiuwei Cui, Marina Cazzaniga, Timucin Cil, Katarzyna J. Jerzak, Christian Fuentes, Tetsuhiro Yoshinami, Alvaro Rodriguez-Lescure, Ahmet Sezer, Andrea Fontana, Valentina Guarneri, Andrea Molckovsky, Marie-Ange Mouret-Reynier, Umut Demirci, Yongqiang Zhang, Olga Valota, Dongrui R Lu, Marcella Martignoni, Janaki Parameswaran, Xin Zhi, Erika P. Hamilton, the VERITAC-2 Study Group*
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer May 31, 2025
In HER2-positive metastatic gastric cancer, trastuzumab deruxtecan led to longer survival and better response than ramucirumab–paclitaxel. Adverse events were common. Lung toxic effects with T-DXd were mainly low grade.
Kohei Shitara, Eric Van Cutsem, Mahmut Gümüş, Sara Lonardi, Christelle de la Fouchardière, Clélia Coutzac, Jeroen Dekervel, Daniel Hochhauser, Lin Shen, Wasat Mansoor, Bo Liu, Lorenzo Fornaro, Min-Hee Ryu, Jeeyun Lee, Cátia Faustino, Jean-Philippe Metges, Josep Tabernero, Fábio Franke, Yelena Y. Janjigian, Fabricio Souza, Lori Jukofsky, Yumin Zhao, Takahiro Kamio, Aziz Zaanan, Filippo Pietrantonio, the DESTINY-Gastric04 Trial Investigators*

RMEI LIGHTNING TALKS

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.

Allergy & Immunology
2021

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.